|
Ahmed AR Sami N
Uncommon manifestations of PV
JEADV 16;313-15 2002 PV, eyes, esophagus, anal, laryngeal, nails, throat, penile, vaginal
Amagai M
Pemphigus as a paradigm of autoimmunity and cell adhesion
Keio J Med 51;133-9 2002 PV, PF, Dsg 1, Dsg3, review, ET
Arteaga LA Prisayanh PS Warren SJP Liu Z, et al
A subset of PF patients exhibits pathogenic autoantibodies against both Dsg-1 & Dsg-3
J Invest dermatol 118;806-11 2002 PF, PV, Dsg 1, Dsg3, fogo selvagem, combo
Bachmeyer C Seoud J Carlotti A Bernard P, et al
BP associated with acute myocarditis
Dermatol 204;161-2 2002 BP, myocarditis
Baroni A Perfetto B Ruocco E Greco R, et al
Cytokine pattern in blister fluid and sera of patients with pemphgus
Dermatol 205;116-21 2002 PV, PF, cytokines, blister fluid, IL-10, IL8, IFN
Baykal C Azizlerli G Thoma-Uszynski S Hertyl M
PV localized to the nose and checks
J Am Acad Dermatol 47;875-80 2002 PV, nose, checks
Beutner EH Pelton S Hashimoto T Xu Y, et al
A nonfatal case and 2 fatal cases of PNP: Can a complement indirect immunofluorescent test help to identify fatal "group A" PNP cases
J Am Acad Dermatol 47; 841-51 2002 PNP, CIIF, group A, fatal
Bhol KC Ahmed AR Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from PV patients Autoimmunity 35;87-91 2002 PV, Dsg 3, IgG1, non-pathogenic
Bickle KM Roark TR Hsu S
Autoimmune bullous dermatoses; a review
Am Fam Practice 65;1861-70 2002 PV, PNP, BP, CP, DH, linear IgA
dermatosis, review
Brenner S Sasson A Sharon O
Pempigus and infections
Clin Dermatol 20;114-8 2002 PV, PF, infections, triggers, HSV
TOP
Bystryn J-C Akman A Jiao D
Limitations in ELISAs for antibodies against Dsg 1 and 3 in patients with pemphigus
Arch Dermatol 138;1252-3 2002 ELISA, Dsg 1, Dsg 3, IIF, IDIF
Bystryn J-C Jiao D Natow S
Treatment of pemphigus with IVIg
J Am Acad Dermatol 47;358-63 2002 PV, IVIg
Bystryn JC
How should pemphigus be treated?
JEADV 16;562-3 2002 PV, PF, treatment, review
Campo-Voegeli A Muniz F Mascaro JM Casais M, et al
Neonatal PV with extensive mucocutaneous lesions from a mother with oral PV
Br J Dermatol 147;801-5 2002 neonatal PV, pregnancy, PV, Dsg 3
Chan LS Ahmed RA Anhalt GJ Bernnauer W, et al
The first international consensus on Mucous membrane pemphigoid (MMP)
Arch Dermatol 138; 370-79 2002 review, MMP, CP, OCP
Cheng SW Kobayashi M Tanikawa A Kinoshita K, et al
Monitoring disease activity in pemphigus with ELISA USING recombinant desmoglein 1 & 3
Br J Dermatol 147;261-5 2002 PV, PF, ELISA dsg 1and 3, disease activity, monitoring
Cohen MA Cohen JJ Kerdel FA
Immunoablative high-dose cyclophosphamide without stem cell rescue in PF
Int J Dermatol 41;340 2002 PF,immunoablative high-dose cyclophosphamide
Cozzani E Cacciaputi M Parodi A Rebora A
Pemphigus following tetanus and diphtheria vaccination
Br J Dermatol 147;188-89 2002 drug induced, PV, tetanus and diphtheria vaccination
Dereure O Bessis D Guillot B Guilhou J-J
Treatment of BP by low-dose methotrexate associated with short term potent topical steroids: an open prospective study of 18 cases
Arch Dermatol 138;1255-56 2002 BP, methotrexate
Dobson-Stone C Fairclough R Dunne E Brown J, et al
Hailey-Hailey disease; molecular & clinical characterization of movel mutation in the ATP2C1 gene J
Invest Dermatol 118; 338-43 2002 Hailey-Hailey disease, ATP21C1 gene
Duong DJ Moxley RT Kellman RM Pincus SH, et al
Thalidomide therapy for CP
J Am Acad Dermatol 47;S193-5 2002 thalidomide, CP
Erickson NI Ellis RL
Neonatal rash due to Herpes Gestationis
NEJM 347;660 2002 herpes gestationis, pregnancy
Femiano F Gombos F Scully C
PV with oral involvement: evalualtion of two different systemic corticosteroid theraputic protocols
JEADV 16;353-56 2002 PV, corticosteroids, treatment
Fueston JC Adams BB Mutasim DF
Cicatricial pemphigoid - induced phimosis
J Am Acad Dermatol 46;S128-9 2002 CP, penis, phimosis
Gelfand JM Werth VP
Treatment of BP with topical corticosteroids: review of a randomized controlled trial
Arch Dermatol 138; 1236-7 2002 BP, topical corticosteroids, treatment
Goldsmith L
Clinical snippets
J Invest Dermatol 119-1215 2002 Dsg 1, Dsg3
Hanakawa Y Amagai M Shirakata Y Yahata Y, et al
Differential effects of Dsg 1 and Dsg 3 on desmosome formation
J Invest Dermatol 119;1231-36 2002
Dsg 1, Dsg 3, desmosomes, PV
Hanakawa Y Matsuyoshi N Stanley JR
Expression of Dsg 1 compensates for genetic loss of Dsg3 in keratinocyte adhesion
J Invest Dermatol 119;27-31 2002 Dsg1, Dsg 3, desmoglein compensation hypothesis
Harman KE Gratian MJ Shirlaw PJ Bhogal BS, et al
The transition of PV in PF: a reflection of changing Dsg 1 & 3 autoantibody levels in PV
Br J Dermatol 146; 684-87 2002 PF, PV, transition
Sullivan TP Elgart GW Kirsner RS
Pemphigus and smoking
Int J Dermatol 41;528-30 2002 PV, PF, smoking
Torzecka JD
Controversies concerning the cure process in patients with PV
JEADV 16;648 2002 PV, cure, remission, esophagus
Toth Gg van de Meer Jb Jonkman Mf
Dexamethasone pulse therapy in pemphigus
J Eur Acad Dematol & Vener 16;606-611 2002 PV, pulse therapy,
dexamethasone
TOP
Tsuji Y Kawahima T Yokota K Tateish Y et al
Clinical and serologic transition from PV to PF demonstrated by demoglein ELISA system
Arch Dermatol 138;95-6 2002 PV, PF, transition
Tsunoda K Ota T Suzuki H Ohyama M, et al
Pathogenic autoantibody production requires loss of tolerance against Dsg 3 in both T and B cells in experimental PV
Eur J Immunol 32;627-33 2002 PV, T cells, B cells, Dsg 3
Wise JL Murray JA
Esophageal manifestations of dermatologic disease
Current Gastro Reports 4;205-12 2002 esophagus, PV, CP
Wojnarowska F Kirtschig G Highet AS Venning VA, et al
Guidelines for the management of BP
Br J Dermatol 147;214-21 2002 BP, review, treatments
Zitouni M Martel P Ben Ayed M Raux G, et al
Pemphigus is not ASSOCIATED with ALLOTYPIC MARKERS of immunoglobulin kappa Genes
Immun 3;50-2 2002 PV, PF, kappa light chains,
Sitaru C Schmidt E Petermann S Munteanu LS, at al
Autoantibodies to BP antigen 180 induce dermal-epidermal seperation in cryosections of human skin
J Invest dermatol 118;664-71 2002 BP, BP antigen 180, hemidesmosome
Stern RS
PB therapy- think globally, act locally
NEJM 346; 364-7 2002 BP, prednisone, topical corticosteroids, clobetasol
TOP
|
Hash KS Rencic A Hernandez MI Hashimoto T, et al
Aggessive immunosuppressive therapy for a refractory case of IgA pemphigus
Arch Dermatol 138;
744-46 2002 IgA pemphigus
Hofmann SC Thoma-Uszynski S Hunziker T Bernard P, et al
Severity and phenotype of BP relates to autoantibody prifile against the NH2-and COOH- terminal regions of the BP180 ectodomain
J Invest Dermatol 119;1065-73 2002 BP, BP180, mucosal lesions, NH2-, COOH- terminal regions of the BP180 ectodomain
Joly P Roujeau J-C Benichou J Picard C et al
A comparison of oral and topical corticosteroids in patients with BP
NEJM 346;321-27 (editorial Stern 364-7) 2002 BP, prednisone, topical corticosteroids, clobetasol
Kacar S Sezgin O Sahin T
PV and ulcerative colitis
Am J Gastroent 97;507-8 2002 PV, UC, ulcerative colitis
Kalayciyan A Engin B Serdaroglu S Mat C, et al
A retrospective analysis of patients with PV associated with pregnancy
Br J Dermatol 147;396-7 2002 PV, pregnancy
Kanwar AJ Kaur S Thami GP
Long term efficacy of dexamethasone-cyclolphosphamide pulse therapy in pemphigus
Dermatol 204; 228-31 2002 dexamethasone - cyclophosphamide pulse therapy, PV, PF
Khandpur S Reddy BS
An unusual association of PV with hyperprolactinemia
Int J Dermatol 41;696-699 2002 PV, hyperprolactinemia
Khumalo NP Murrell DF Wojnarowska F Kirtschig G
A systematic review of treatment for BP
Arch Dermatol 138;385-89 2002 BP, treatment, tetracycline
Kirtschig G Murrell D Wojnarowska F Khumalo N
Interventions for MMP/CP and epidermolysis bulllosa acquisita (EBA)
Arch Dermatol 138;380-84 2002 MMP, CP, EBA, review
Korman NJ
Various letters concerning article by Jolly Oral and topical corticosteroids in BP
NEJM 347;143-45 2002 Korman,N Pemphigus J Am Acad Dermatol 18;1219-38 1988 review, PV, PF
Liu Z
Are anti-BP180 IgG1 or IgG4 autoantibodies pathogenic?
J Invest Dermatol 119;989-90 2002 BP, BP230, BP180, anti-BP180 IgG1 or IgG4 autoantibodies, compliment
Ljubojevic S Lipozen J, et al
PV: a review of treatment over a 19-year period
J Eur Acad Dermatol & Venereol 16;599-603 2002 PV, treatment
Martel P Gilbert GD Busson M Loiseau P, et al
Epistasis between DSG1 and HLAII genes in PF Genes
Immun 3;205-10 2002 PF, Dsg 1, HLA epistasis,PV, HLA DRB1*0102,0404,1402, 1406,C/C809
Metry DW Hebert AA Jordon RE
Nonendemic PF in children
Am Acad Dermatol 46;419-22 2002 PF, children, hydroxycloroquine
Mimouni D Anhalt GJ Lazarova Z Aho S, et al
Paraneoplastic pemphigus (PNP) in children and adolescents
Br J Dermatol 147;725-32 2002 PNP, children, adolescents, castleman's disease, plakin protein
Moesta AK Lin M-S Diaz LA Sinha AA
T cell receptor ß chain gene usage in endemic PF (fogo Selvagem)
J Invest Dermatol 119;377-83 2002 PF, FS, T cells, TCR, vaccine
Moyer P Grando SA
Beyound immunosupppression: study shows corticosteroids' role in pemphigus
Dermatol World ;34 2002 PV, teatments, microarrays,
Muhammad JK Lewis MA Crean SJ
Oral PV occuring during pregnancy
J Oral Pathol Med 31;121-4 2002 PV, oral involvement, pregnancy
Mutasim DF
Treatment considerations while awaiting the ideal BP trial
Arch Dermatol 138;404 2002 BP, treatment
Ohyama M Amagai M Tsunoda K Ota T, et al
Immunologic and histopathologic characterization of an active disease model for PV
J Invest Dermatol 118;199-204 2002 PV, disease model
TOP
Oiso N Yamashita C Yoshioka K Amagai M, et al
IgG/IgA pemphigus with IgG and IgA antidesmoglein 1 antibodies detected by ELISA
Br J Dermatol 147;1012 2002 IgG/IgA pemphigus, Dsg 1
Organizing committee: Bystryn J-C Anhalt G Diaz L, and Stanley J
Abstracts of the National Pemphigus Foundation and The American Autoimmune Related Disease Association International meeting : Pemphgus as a model of organ-specific humoral autoimmune diseases
J Invest Dermatol 118;734-40 2002 PV, PF, review, NIH meeting
Palleschi GM Cipollini EM Lotti T
Development of oesophageal involvement in a subject with PV; a case report and review of theliterature
JEADV 16;404-408 2002 PV, esophagus, oesophagus, endoscopy
Parodi A Cozzani E Milesi G Drosera M et al
Fosinopril as a possible pemphigus-inducing drug
Dermatol 204;139-41 22002 PV, drug-induced, fosinopril
Rzany B Partscht K Jung M KippesW, et al
Risk factors for lethal outcome in patients with BP
Arch Dermatol 138; 903-8 2002 BP, risk factors, death
Sacher C Rubbert A Konig C Scharffetter-Kochanek K, et al
Treatment of recalcitrant CP with the tumor necreosis factor alpha antagonist etanercept
J Am Acad Dermatol 46; 113-5 2002 CP, etanercept, TNF- alpha
Salopek TG Logsetty S Tredget EE
Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening PV with implications in the pathogenesis of the disorder
J Am Acad Dermatol 47;785-8 2002 PV, rituximab, rituxan
Sami N Bhol KC Beutner EH Plunkett RW, et al
Diagnostic features of PV in patients with BP
Dermatol 204;108-117 2002 PV, BP, simultaneous, anti-Dsg 1 and 3 antibodies
Sami N Qureshi A Ahmed AR
Steroid sparing effect of IVIg therapy in patients with PF
Eur J Dermatol 12;174-8 2002 PF, IVIg, steroids
Sami N Qureshi A Ruocco E Ahmed AR
Cortocosteroid-sparing effect of IVIg therapy in patients with PV
Arch Dermatol 138;1158-62 2002 PV, IVIg,
Schlesinger N Katz M Ingl
A Nail Involvement in PV
Br J Dermatol 146;836 2002 PV, nails
Schwartz RA Majeewski S Majewski SS
PF
eMedicine online: www.emedicine.com/derm//topic318.htm 2002 PF, review
Scully C ChallacombSJ
PV: update on etiopathogenesis, ora manifestations, and management
Crit Rev Oral Biol Med 13;397-408 2002 PV, oral, review
Shimanovich I Skrobek C Rose C Nie Z, et al
Pemphigus gestationis with the predominat involvement of oral mucous membranes and IgA autoantibodies targeting the C-terminus of BP180
J Am Acad Dermatol 47;780-4 2002 PG, pregnancy, IgA, BP180
Shimizu A Ishiko A Ota T Tsunoda K, et al
Ultrastructural changes in mice activily producing antibodies to Dsg 3 parallel those in patients with PV
Arch Dermatol Res 294;318-23 2002 PV, Dsg 1, Dsg 3, mice model, Dsg
knockout mice, murine model, experimental model
TOP
|
